Transcript No Slide Title

Partnerships That Accelerate Innovation:
1+1=11
June 12, 2013
0
Presentation Overview
 The Issues
 New Opportunities for Collaboration
 How Massachusetts is Supporting New
Opportunities for Collaboration
1
The Issues – A Brief Summary
 Drug pipelines are running dry and many “blockbuster
medicines” are about to lose patent protection
 Traditional drug-development processes at big pharma are
expensive and inefficient; the traditional business model at
big pharma also is expensive and inefficient
 Acquisition of biotech firms by big pharma is not solving
the problem
 Solutions to some of the most pressing problems lie at the
intersection of diagnostiscs, biopharma, medical
technology (devices), and computing
Collaboration is an increasingly important solution!
2
 The Issues
 New Opportunities for Collaboration
 How Massachusetts is Supporting New
Opportunities for Collaboration
3
Public-Private Partnerships
Collaborations that are:
 Focused on shared challenges that are critical for
progress…
 …and are increasingly difficult for a single sector
to tackle, and/or finance alone…
 …where solutions can benefit both the public and
private sector (and the broader economy)
4
Pre-competitive Consortia
Collaborations that are:
 Focused on shared challenges that are critical for
progress…
 …and are increasingly difficult for a single
organization to tackle alone…
 …but cannot be exploited as a standalone profitmaking opportunity for any individual participant
5
Models of Pre-competitive Consortia*
1. Open source initiatives
3. Discovery-enabling consortia
4. Public-private consortia for
knowledge creation
5. Prizes
6. Innovation incubators/insourcing
7. Industry complementor
relationships
Who Participates/Contributes
2. Industry consortia for R&D process
innovation
Restricted
Open
Open
8. Virtual pharma companies
Restricted
Who Accesses Outputs
*Altschulergray (2010)
6
International Collaboration
In mature industry sectors, innovation inevitably requires
international collaboration
 No country has all the expertise, tools, models, cohorts, etc. to address
the increasing challenge of discovery and development
 Knowledge creation is occurring all around the world and has to be
rapidly disseminated
 Research scientists seek expertise where they can find it – they are not
“place based”
No sector alone has the power to achieve these goals
as well: public and private sectors also must increase
their collaboration!
7
 The Issues
 New Opportunities for Collaboration
 How Massachusetts is Supporting New
Opportunities for Collaboration
8
Massachusetts: A Global Leader in Life Sciences
The Massachusetts Life Sciences Supercluster:
 The world’s leading innovation pipeline: The Milken Institute’s 2010
ratings rank Massachusetts #1 for technology innovation
 World-class academic and medical institutions leading the way in life
sciences research
 A talented workforce
 95,000 workers in life sciences; 50% biopharma job growth in past decade
 All industry sectors -- biotechnology, pharmaceuticals, medical devices,
diagnostics and bioinformatics
 Government leadership, through our state’s 10-year, $1 billion Life
Sciences Initiative (enacted by the Massachusetts Legislature in June 2008)
9
The Massachusetts Life Sciences Center: Who We
Are and What We Do
The Massachusetts Life Sciences Center
develops and offers creative programs that
fund innovation-driven economic
development initiatives in the Massachusetts
life sciences cluster, but also may have
relevance for other “innovation” sectors.
Mission:
 Serve as the “hub” of the Massachusetts life sciences
Supercluster
 Encourage innovation through investments in good science and
good business
 Strengthen and protect Massachusetts’ global leadership position
in the life sciences
 Accelerate the commercialization of promising treatments,
therapies and cures
 Create jobs and drive economic development
10
The MLSC Invests to Close Gaps Across the
Innovation Life Cycle...
Discovery
Development
Delivery
The MLSC Strategy:
Reduce barriers, fill gaps and promote collaboration across the life
sciences innovation process
• Promote and fund convening and collaboration
• Partner with and leverage private sector stakeholders
• Invest in early stage companies (pipeline and external innovation)
• Support workforce development and training
• Build capacity, infrastructure and unique resources in Massachusetts
11
…and Coalesce the Massachusetts Life Sciences
“Cluster” into a “Ecosystem”
Life sciences innovation
thrives in
Massachusetts because
of the great
concentration of
universities, research
hospitals, educated
workers, entrepreneurs,
mature companies and a
strong investment
community.
In a high performing
innovation clusters
these components work
well individually and
together as an
ecosystem
550
430+
Biopharma
Biotech
Companies
400
Medtech
Companies
122
122
Colleges &
Universities
Universities
Top 5
Top
5
1st in
Educational
Education
Level of
workforce
Workforce (US)
1st in
NIH funded
NIH funded
Research
Research
Hospitals
Hospitals
Venture Capital
& SBIR
federalfunds
research
per
funds
worker
per worker
MLSC
Investments
12
Life Sciences Initiative Investment Tools
• 10 years
• $1 billion
Investment
13
The MLSC Board of Directors –
Public and Private Sector Stakeholders Provide Governance
 Secretary of Housing and Economic Development
 Gregory Bialecki
 Secretary of Administration and Finance
 Jay Gonzalez
 President of the University of Massachusetts System
 Robert Caret, Ph.D.
 A CEO of a Massachusetts-based life sciences corporation
 Abbie Celniker, Ph.D., CEO, Eleven Biotherapeutics
 A researcher involved in the commercialization of biotechnology,
pharmaceuticals or medical diagnostic products
 Lydia Villa-Komaroff, Director and CSO, Cytonome/ST
 A physician licensed to practice medicine in the Commonwealth and
affiliated with an academic medical center
 Edward Benz, M.D., President & CEO, Dana-Farber Cancer Institute
 A person with financial expertise in the life sciences
 Joshua Boger, Ph.D., Founder & CEO (Retired), Vertex
14
The MLSC Scientific Advisory Board FY ‘13
CHAIR: Harvey Lodish, Ph.D.,
Whitehead Institute and Massachusetts Institute of Technology (MIT)
Academia
•
James J. Collins, Ph.D.,
•
Boston University
•
John M. Collins, Ph.D.,
Center for Integration of Medicine &
Innovative Technology (CIMIT)
•
Robert D’Amato, M.D., Ph.D.,
Center for Macular Degeneration
Research , Harvard Medical School
and Boston Children’s Hospital
•
Rainer Fuchs, Ph.D.,
•
•
•
Harvard Medical School, HarvardMIT Division of Health Sciences
and Technology (HST) and
Massachusetts General Hospital
•
Judith Lieberman, Ph.D.,
•
Lita L. Nelsen,
•
Barbara Osborne, Ph.D.,
•
Jonathan Fleming, M.P.A.,
Oxford Bioscience Partners
David Walt, Ph.D.,
Tufts University School of
Medicine
•
Philip Zamore, Ph.D.,
•
Henry Kay,
Boston Harbor Angels
Carmichael Roberts, Ph.D., M.B.A.,
North Bridge Venture Partners
Lauren Silverman, Ph.D.,
Novartis Option Fund
James Barry, Ph.D.,
Entrepreneurs
Arsenal Medical
Immune Disease Institute, Boston
Children’s Hospital and Harvard
Medical School
T. (Teo) Dagi, M.D., M.B.A.,
HLM Venture Partners
Industry
•
Kevin Bitterman, Ph.D.,
Polaris Venture Partners
•
Dalia Cohen, Ph.D.,
ALN Associates
Massachusetts Institute
of Technology (MIT)
•
•
Glenn R. Gaudette, Ph.D.,
Worcester Polytechnic Institute
(WPI)
•
Guillermo Tearney, M.D.,
Ph.D.,
UMass Medical School
Harvard Medical School
•
Venture Capital
José-Carlos GutiérrezRamos, Ph.D.,
•
Alison Taunton-Rigby, Ph.D.
RiboNovix, Inc.
Pfizer
•
Dale Larson,
Draper Laboratory
UMass Amherst
•
Alan Smith, Ph.D.,
Formerly of Genzyme, a Sanofi
Company
15
Gaining Leverage: Public-Private Partnership
Life Sciences Center’s Impact: June ‘08 – May ‘13
Corporate Investors
Public Dollars Invested/
Committed
= $461 M
Matching
Investments
Attracted
= $1.2 B
NIH
Private Foundations
Grants to Academic
Organizations and
Medical Centers
Institutes
Grants for “Shovel
Ready” Capital
Projects
Investments in
Life Sciences
Companies
Other Private
Investors
Academic
Institutions
16
Creating Opportunities for New Partnership Models
Between Academia and Industry
Objective: encourage industry and Massachusetts academic
institutions to explore new models of collaboration in
discovery and development.
 Awards are made on a competitive basis. Key evaluation
criteria include:
 Impact of the focus area (product/technology)
 Novel aspects of the academic-industry collaboration
 Acceleration of “bench to bedside”
 Focus areas to date have included therapeutics, devices,
materials and tools
The Center has awarded 8 grants totaling $4.76 million
Industry partners provide a (minimum) 1:1 match
17
Consortia in the Pre-Competitive Space
 Massachusetts is a center of excellence in the field of biomedical
neuroscience with world leaders representing all major fields of
neurobiology and neurology.
 The combination of basic neuroscience, translational, and clinical
research distributed across more than a dozen world-renowned
institutions amounts to what may be the highest density of
neuroscience research in the world.
 This provides a rich and fertile environment within which to advance
our understanding and treatment of neurological disease.
 The Massachusetts Life Sciences Neuroscience Consortium (MLSNC)
is a pioneering new model that is designed to leverage this rich
environment to:
 Accelerate pre-clinical research available to the pharmaceutical industry
 Introduce academic researchers to targeted research
 Facilitate new models of industry-academic partnership
18
MLSC Neuroscience Consortium
Objective: Create a pioneering new model of collaboration designed to
leverage Massachusetts’ rich neuroscience environment to:
 Accelerate pre-clinical research available to the pharmaceutical industry
 Introduce academic researchers to targeted research
 Facilitate new models of industry-academic partnership
 Massachusetts’ basic neuroscience, translational, and clinical research
distributed across more than a dozen world-renowned institutions
amounts to what may be the highest density of neuroscience research
in the world.
 Neuroscience Consortium Charter members:




Abbott
Biogen-Idec
EMD Serono
Janssen Research (Johnson and
Johnson)
 Merck
 Pfizer
 Sunovion (Dainippon
Sumitomo)
19
Consortia in the Pre-Competitive Space
Why is this Consortium Different?
 Proposed projects will be short-term and results-oriented.
Timelines/milestones, budgets and objectives will be clearly defined by
the industry sponsors
 Industry sponsors will identify common standards, e.g. levels of
validation necessary for a project objective to be considered
“complete.
 Industry sponsors will work in collaboration with PIs and their teams;
sponsors also will contribute tools, data and other resources to the
project teams to expedite their work
 Results are shared with all participants; sponsors and PIs will have
access to the use of any tools developed by each project
 Industry sponsors will determine their interest in validated targets as
projects are completed. Co-development among consortium members
is an option.
20
Consortia in the Pre-Competitive Space
Role of the Massachusetts Life Sciences Center
 The Massachusetts Life Sciences Center (MLSC) will use its convening
power to reduce barriers to collaboration and to expedite access to the
research community
 By acting as an intermediary, the MLSC also will enable industry to
provide funding ‘at arms length’, thereby removin some of the
administrative complications of direct corporate sponsorship of
academic lab research
 The MLSC will “staff” the Consortium so that all administrative costs
are subsidized by the state and sponsors’ investments will be fully
directed to funding projects
The Consortium received nearly 100 proposals in response to
the initial solicitation and chose seven (7) projects to fund. For
each project, a member(s) of the Consortium will work with the
PI and his/her team.
21
International Partnership Assistance Portal (IP-ap)
Objective: Make it easier for international and Massachusetts companies to
identify and pursue potential partnerships .




Free, password-protected, cloud-based
portal -- Create your user profile at
https://partnering.masslifesciences.com
Open to MA-based life sciences
companies and international life sciences
companies
Companies describe their business and
qualities they are seeking in a partner
Searchable database - MA companies
can search MA and international
companies, and international companies
can search MA companies
Massachusetts is open for collaboration:
24/7, 365 days a year!
22
International Collaborative Industry Program:
Objectives and Approach
Our
belief:
1
1
2
11
Approach:
 Focus on collaborative life sciences industry
projects in late R&D or development
 Implement the collaboration through MLSC
and Partner agencies in other countries
 Execute through a competitive solicitation to
select promising project(s) between MAbased and non-U.S. based companies
 Funding from MLSC to MA companies
 Funding from Partner agencies to the
international company partners
 Funding from each of the partner companies
23
International Collaborative Industry Program:
Program Model
Massachusetts
Company
Min.100k
$
MLSC will
match MA
company
contribution
Non US-based
Company
Min. 100k
After a min. of
$100k/project the
rest is determined
by the agency
$
Partner Agency
Min. 100k/project, Max. 500k
Min. 100k /project
24
International Collaborative Industry Program:
Program at a Glance
Objective: Jointly invest in international and Massachusetts R&D
partnerships .
 Collaboration between MA life sciences company and a life sciences
company from another participating geography
 Late R&D stage with a goal of commercialization
 Each company must have a well-defined role, set of responsibilities and
work plan
 The minimum grant level that Massachusetts applicants may be
awarded by MLSC is $100,000 and the maximum will be $500,000
 MA company contribution must meet or exceed MLSC grant
 Other agencies specify the terms of their funding to local companies
and must provide minimum of $100,000 funding
 Program will involve a two-phased competitive RFP
 To receive funding, a final IP Agreement between the two companies
must be submitted
25
International Collaborative Industry Program (ICIP)
Launch at BIO 2013
 The announcement of ICIP included high-level representatives from our
partnering regions including:
 Alsace Region in France
 Quebec Province in Canada
 Victoria State in Australia
 Wallonia Region in Belgium
26
Keeping in Touch
www.masslifesciences.com
• News updates
• Program Information
• Application portal
Life Sciences Center Email List
• 4,500 recipients
• Weekly event listings
• Sign up today!
27